Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials

Abstract

Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA), including azacitidine, decitabine, or oral decitabine/cedazuridine. Many attempts using HMA-based combinations have failed to improve upon HMA monotherapy. Although promising efficacy was observed in early-phase clinical trials with several agents, subsequent randomized phase 3 trials failed to confirm improvements in complete response rates or overall survival. In this review, we discuss lessons learned from the recently reported negative trials of azacitidine in combination with eprenetapopt (APR-246), magrolimab, pevonedistat, sabatolimab, tamibarotene, and venetoclax. First, we make a case for emphasizing biological classification rather than disease risk status alone to select patients for HR-MDS trials. Second, we argue that patients with TP53-inactivated MDS and chronic myelomonocytic leukemia should be treated in dedicated clinical trials. Alternatively, if TP53-inactivated MDS is included in HR-MDS trials, then randomization stratification by TP53 inactivation status should be considered. Third, we caution against ignoring signals of excessive toxicity and premature discontinuation of investigational agent observed in early-phase trials. Fourth, we show that the International Working Group (IWG) 2006 response criteria, long used in HR-MDS trials, can both overestimate and underestimate the true therapeutic benefit. Instead, we advocate for using the IWG 2023 response criteria to better capture clinically meaningful benefits in HR-MDS. Lastly, we emphasize the need for the scientific community to access patient-level data and samples from failed phase 3 trials in an efficient and expedited fashion to inform the development of subsequent trials.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.2025029727

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 64 references

Research works printed but not linked: 2

  1. Bernard, 2020, Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes, Nat Med, 26, 1549, 10.1038/s41591-020-1008-z · DOI · Paper page
  2. Sallman, 2023, Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study, J Clin Oncol, 41, 2815, 10.1200/JCO.22.01794 · DOI · Paper page

Cited by

See all 14

Metadata

Authors
Stahl, M., & Zeidan, A. M.
Affiliations
Yale Cancer Center (US)
Corresponding author
Zeidan, Amer M.
Venue
Blood
Published
2026-02-19
Volume
147
Issue
8
Pages
811-820
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4415767294
Cited by
14
References
64
Citations by year
2026: 14
FWCI
2.36
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
high-risk myelodysplastic syndrome, drug development, hypomethylating agents, azacitidine, APR-246, magrolimab, pevonedistat, tamibarotene, venetoclax, p53 inactivation, chronic myelomonocytic leukemia, taxonomy (general classification scheme)
MeSH terms
Drug Development, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Humans, Myelodysplastic Syndromes, Clinical Trials, Phase III as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. https://app.cochat.ai/papers/10.1182/blood.2025029727
The paper
Stahl, M., & Zeidan, A. M. (2026). The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. Blood. https://doi.org/10.1182/blood.2025029727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.